166 related articles for article (PubMed ID: 24473115)
1. Arylesterase phenotype-specific positive association between arylesterase activity and cholinesterase specific activity in human serum.
Aoki Y; Helzlsouer KJ; Strickland PT
Int J Environ Res Public Health; 2014 Jan; 11(2):1422-43. PubMed ID: 24473115
[TBL] [Abstract][Full Text] [Related]
2. Cholinesterase, arylesterase, and lipoprotein parameters in twins.
Boman H
Acta Genet Med Gemellol (Roma); 1980; 29(4):281-7. PubMed ID: 7197453
[TBL] [Abstract][Full Text] [Related]
3. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk.
Tang WH; Hartiala J; Fan Y; Wu Y; Stewart AF; Erdmann J; Kathiresan S; ; Roberts R; McPherson R; Allayee H; Hazen SL
Arterioscler Thromb Vasc Biol; 2012 Nov; 32(11):2803-12. PubMed ID: 22982463
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the serum paraoxonase/arylesterase polymorphism in a Turkish population.
Karakaya A; Suzen S; Sardas S; Karakaya AE; Vural N
Pharmacogenetics; 1991 Oct; 1(1):58-61. PubMed ID: 1668963
[TBL] [Abstract][Full Text] [Related]
5. Interindividual variations in enzymes controlling organophosphate toxicity in man.
Mutch E; Blain PG; Williams FM
Hum Exp Toxicol; 1992 Mar; 11(2):109-16. PubMed ID: 1349216
[TBL] [Abstract][Full Text] [Related]
6. Effect of peroxisome proliferating hypolipidemic agents on serum activity levels of arylesterase and cholinesterase in rats and mice.
Butler EG; England PJ; Williams GM
Res Commun Chem Pathol Pharmacol; 1988 Apr; 60(1):125-8. PubMed ID: 3381006
[TBL] [Abstract][Full Text] [Related]
7. Paraoxon hydrolysis in human serum mediated by a genetically variable arylesterase and albumin.
Ortigoza-Ferado J; Richter RJ; Hornung SK; Motulsky AG; Furlong CE
Am J Hum Genet; 1984 Mar; 36(2):295-305. PubMed ID: 6324579
[TBL] [Abstract][Full Text] [Related]
8. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities.
Gan KN; Smolen A; Eckerson HW; La Du BN
Drug Metab Dispos; 1991; 19(1):100-6. PubMed ID: 1673382
[TBL] [Abstract][Full Text] [Related]
9. Levels of paraoxonase and arylesterase activities and malondialdehyde in workers exposed to ionizing radiation.
Serhatlioglu S; Gursu MF; Gulcu F; Canatan H; Godekmerdan A
Cell Biochem Funct; 2003 Dec; 21(4):371-5. PubMed ID: 14624476
[TBL] [Abstract][Full Text] [Related]
10. A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate.
Haagen L; Brock A
Eur J Clin Chem Clin Biochem; 1992 Jul; 30(7):391-5. PubMed ID: 1525262
[TBL] [Abstract][Full Text] [Related]
11. Distribution profiles of paraoxonase and cholinesterase phenotypes in a Spanish population.
Hernández AF; Gonzalvo MC; Gil F; Rodrigo L; Villanueva E; Pla A
Chem Biol Interact; 1999 May; 119-120():201-9. PubMed ID: 10421454
[TBL] [Abstract][Full Text] [Related]
12. Assessment of serum paraoxonase and arylesterase activity in patients with endometrial cancer.
Arioz DT; Camuzcuoglu H; Toy H; Kurt S; Celik H; Erel O
Eur J Gynaecol Oncol; 2009; 30(6):679-82. PubMed ID: 20099504
[TBL] [Abstract][Full Text] [Related]
13. Decreased serum paraoxonase and arylesterase activities in patients with rosacea.
Takci Z; Bilgili SG; Karadag AS; Kucukoglu ME; Selek S; Aslan M
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):367-370. PubMed ID: 24854673
[TBL] [Abstract][Full Text] [Related]
14. [Age related decrease of high density lipoproteins (HDL) in women after menopause. Quantification of HDL with genetically determined HDL arylesterase in women with healthy coronary vessels and in women with angiographically verified coronary heart disease].
Chemnitius JM; Winkel H; Meyer I; Schirrmacher K; Armstrong VW; Kreuzer H; Zech R
Med Klin (Munich); 1998 Mar; 93(3):137-45. PubMed ID: 9564161
[TBL] [Abstract][Full Text] [Related]
15. [Cholinesterase, arylesterase and proteinuria. A clinical trial in glomerular and tubular proteinuria (author's transl)].
Vincent D; Magron J
Clin Chim Acta; 1978 Nov; 90(1):1-5. PubMed ID: 719886
[TBL] [Abstract][Full Text] [Related]
16. The effect of 2-(o-cresyl)-4H-1:3:2-benzodioxaphosphorin-2-oxide on tissue cholinesterase and carboxylesterase activities of the rat.
Jimmerson VR; Shih TM; Maxwell DM; Kaminskis A; Mailman RB
Fundam Appl Toxicol; 1989 Oct; 13(3):568-75. PubMed ID: 2612789
[TBL] [Abstract][Full Text] [Related]
17. The polymorphic paraoxonase/arylesterase isozymes of human serum.
La Du BN; Eckerson HW
Fed Proc; 1984 May; 43(8):2338-41. PubMed ID: 6325253
[TBL] [Abstract][Full Text] [Related]
18. Tissue-specific effects of chlorpyrifos on carboxylesterase and cholinesterase activity in adult rats: an in vitro and in vivo comparison.
Chanda SM; Mortensen SR; Moser VC; Padilla S
Fundam Appl Toxicol; 1997 Aug; 38(2):148-57. PubMed ID: 9299188
[TBL] [Abstract][Full Text] [Related]
19. Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia.
Aslan M; Kosecik M; Horoz M; Selek S; Celik H; Erel O
Atherosclerosis; 2007 Apr; 191(2):397-402. PubMed ID: 16684543
[TBL] [Abstract][Full Text] [Related]
20. Serum paraoxonase and arylesterase activities in patients with epithelial ovarian cancer.
Camuzcuoglu H; Arioz DT; Toy H; Kurt S; Celik H; Erel O
Gynecol Oncol; 2009 Mar; 112(3):481-5. PubMed ID: 19101714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
